Koike Ryousuke, Sawahata Michiru, Nakamura Yosikazu, Nomura Yushi, Katsube Otohiro, Hagiwara Koichi, Niho Seiji, Masuda Norihiro, Tanaka Takaaki, Sugiyama Kumiya
Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital, Utsunomiya 329-1193, Japan.
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Shimotsuga 321-0293, Japan.
Vaccines (Basel). 2022 Mar 15;10(3):451. doi: 10.3390/vaccines10030451.
We aimed to determine the relationship between vaccine-related adverse effects and antibody (Ab) titers from 3 to 6 months after the second dose of the BNT162b2 coronavirus disease 2019 (COVID-19) mRNA vaccine (Pfizer/BioNTech) in Japan.
We enrolled 378 healthcare workers (255 women and 123 men) whose Ab titers were analyzed 3 and 6 months after the second dose in our previous study and whose characteristics and adverse effects were collected previously by using a structured self-report questionnaire.
The workers' median age was 44 years. Although injection-site symptoms occurred with almost equal frequency between the first and second doses, systemic adverse effects, such as general fatigue and fever, were significantly more frequent after the second dose than after the first dose. Multivariate analysis showed that fever was significantly correlated with female participants for the second dose (odds ratio (OR), 2.139; 95% confidence interval (95% CI), 1.185-3.859), older age for the first dose (OR, 0.962; 95% CI, 0.931-0.994) and second dose (OR, 0.957; 95% CI, 0.936-0.979), and dyslipidemia for the first dose (OR, 8.750; 95% CI, 1.814-42.20). Age-adjusted Ab titers at 3 months after vaccination were 23.7% and 23.4% higher in patients with a fever than in those without a fever after the first and second dose, respectively. In addition, age-adjusted Ab titers at 3 and 6 months after the second dose were, respectively, 21.7% and 19.3% higher in the group in which an anti-inflammatory agent was used than in the group without the use of an anti-inflammatory agent.
Participants with systemic adverse effects tend to have higher Ab titers from 3 to 6 months after the second dose of the BNT162b2 vaccine. Our results may encourage vaccination, even among people with vaccine hesitancy related to relatively common systemic adverse effects.
我们旨在确定在日本接种第二剂BNT162b2 2019冠状病毒病（COVID-19）mRNA疫苗（辉瑞/生物科技公司）后3至6个月，疫苗相关不良反应与抗体（Ab）滴度之间的关系。
我们招募了378名医护人员（255名女性和123名男性），他们的抗体滴度在我们之前的研究中于第二剂接种后3个月和6个月进行了分析，并且他们的特征和不良反应之前通过使用结构化的自我报告问卷进行了收集。
这些工作人员的中位年龄为44岁。虽然第一剂和第二剂接种后注射部位症状出现的频率几乎相同，但全身不良反应，如全身乏力和发热，在第二剂接种后比第一剂接种后明显更频繁。多因素分析显示，发热与第二剂接种的女性参与者显著相关（优势比（OR），2.139；95%置信区间（95%CI），1.185 - 3.859），与第一剂接种时年龄较大显著相关（OR，0.962；95%CI，0.931 - 0.994）以及与第二剂接种时年龄较大显著相关（OR，0.957；95%CI，0.936 - 0.979），并且与第一剂接种时患有血脂异常显著相关（OR，8.750；95%CI，1.814 - 42.20）。接种疫苗后3个月时，发热患者的年龄调整后抗体滴度在第一剂和第二剂接种后分别比未发热患者高23.7%和23.4%。此外，在第二剂接种后3个月和6个月时，使用抗炎药组的年龄调整后抗体滴度分别比未使用抗炎药组高21.7%和19.3%。
出现全身不良反应的参与者在接种第二剂BNT162b2疫苗后3至6个月往往具有更高的抗体滴度。我们的结果可能会鼓励人们接种疫苗，即使是那些因相对常见的全身不良反应而对疫苗犹豫不决的人。
